SCHEMBL21200345

SCHEMBL21200345

Cc1cc(C(=O)Nc2cccc(C(C)(C)Cc3nncn3C)c2)nc(C2CC2)n1

nearest known ligand 0.70

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ CBLB Q13191 20/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29867197 1.00 CBLB (0.70) CBLB
SCHEMBL23033101 0.87 CBLB (0.64) CBLB
SCHEMBL22850738 0.84 CBLB (0.73) CBLB
SCHEMBL21212531 0.83 CBLB (0.72) CBLB
SCHEMBL21212207 0.82 CBLB (1.00) CBLB
SCHEMBL29866823 0.82 CBLB (1.00) CBLB
SCHEMBL29866645 0.82 CBLB (1.00) CBLB
SCHEMBL21212174 0.82 CBLB (1.00) CBLB
SCHEMBL21212513 0.82 CBLB (1.00) CBLB
SCHEMBL29867637 0.82 CBLB (1.00) CBLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3743063-A1 INHIBITORS OF CBL-B AND METHODS OF USE THEREOF Nurix Therapeutics, Inc. (US) 2020-12-02 — — EP disclosed
WO-2019148005-A1 INHIBITORS OF CBL-B AND METHODS OF USE THEREOF NURIX THERAPEUTICS, INC. (US) 2019-08-01 — — WO disclosed
Send feedback